Trade Insights Today - Investing and Stock News
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
No Result
View All Result
Trade Insights Today - Investing and Stock News
No Result
View All Result
Home Latest News

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by
November 26, 2024
in Latest News
0
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
Previous Post

Nvidia Stock Slumps as Dow Futures Edge Lower

Next Post

Stop funding the woke and the stupid

Next Post
Stop funding the woke and the stupid

Stop funding the woke and the stupid

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • Trending
    • Comments
    • Latest
    Buy Bitcoin Under $100K Before The Next Bull Run

    Buy Bitcoin Under $100K Before The Next Bull Run

    April 22, 2025
    KIATOKEN ICO (KIA): Transforming Philanthropy with Crypto

    KIATOKEN ICO (KIA): Transforming Philanthropy with Crypto

    April 3, 2024
    Consumers are tired of price increases. Big brands are paying attention.

    Consumers are tired of price increases. Big brands are paying attention.

    February 23, 2024
    Trump dismisses Musk’s political ambitions as ‘ridiculous’ in sharp rebuke

    Trump dismisses Musk’s political ambitions as ‘ridiculous’ in sharp rebuke

    0
    Rite Aid is closing more than 150 stores as part of its bankruptcy process

    Rite Aid is closing more than 150 stores as part of its bankruptcy process

    0
    Here are the nine Republicans running for House speaker

    Here are the nine Republicans running for House speaker

    0
    Trump dismisses Musk’s political ambitions as ‘ridiculous’ in sharp rebuke

    Trump dismisses Musk’s political ambitions as ‘ridiculous’ in sharp rebuke

    July 7, 2025
    Iran still wants a nuclear weapon despite ‘serious damage’ from US, Israeli strikes: expert warns

    Iran still wants a nuclear weapon despite ‘serious damage’ from US, Israeli strikes: expert warns

    July 6, 2025
    Democrats project doom and gloom, not celebration, with July 4 messages

    Democrats project doom and gloom, not celebration, with July 4 messages

    July 5, 2025
    • About us
    • Contact Us
    • Email Whitelisting
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact Us
    • Email Whitelisting
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2024 Tradeinsightstoday.com

    No Result
    View All Result
    • Investing
    • Latest News
    • Editor’s Pick
    • Economy

    Copyright © 2024 Tradeinsightstoday.com